A potent, cell-permeable broad spectrum inhibitor of protein kinases. Inhibits CaM kinase (IC50 = 20 nM), myosin light chain kinase (IC50 = 1.3 nM), protein kinase A (IC50 = 7 nM), protein kinase C (IC50 = 0.7 nM), and protein kinase G (IC50 = 8.5 nM). Also inhibits platelet aggregation induced by collagen or ADP but has no effect on thrombin-induced platelet aggregation. Induces apoptosis in human malignant glioma cell lines. Arrests normal cells at the G1 checkpoint.
100 μg in Plastic ampoule
Packaged under inert gas
Cell permeable: yes
Product competes with ATP.
Target IC50: 7 nM, 20 nM, 1.3 nM, 700 pM, 8.5 nM, against protein kinase A , CaM kinase, myosin light chain kinase, protein kinase C, and protein kinase G, respectively
Toxicity: Irritant (B)
A 1 mM (100 µg/214 µl) solution of Staurosporine (Cat. No. 569397) in DMSO.
Following initial thaw, aliquot, purge with inert gas, and freeze (-70°C).
Couldwell, W.T., et al. 1994. FEBS Lett.345, 43.
Nishimura, H. and Simpson, I.A. 1994. Biochem. J.302, 271.
Bruno, S., et al. 1992. Cancer Res.52, 470.
Kiss, Z. and Deli, E. 1992. Biochem. J.288, 853.
Vitale, M.L., et al. 1992. Neuroscience51, 463.
Hoffman, R. and Newland, E.S. 1991. Cancer Chemotherap. Pharmacol.28, 102.
Oka, S., et al. 1986. Agric. Biol. Chem.50, 2723.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany